|Day Low/High||71.95 / 73.13|
|52 Wk Low/High||70.83 / 104.79|
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that it has submitted a New Drug Application (NDA) to the U.
It can take many months or quarters before the market recognizes the value of a downtrodden name.
Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'
What's in, what's out and who should thrive in the new political landscape.
Jim Cramer says he prefers Celgene to Gilead, and Walgreens Boots Alliance to Express Scripts.
Jim Cramer remains a fan of industrials, transports, banks and domestic oil producers.
The real story is in the stocks the pros hate.
WOR is in a sweet spot for this rally, and NUE looks good, too, says Jim Cramer.
The number and magnitude of earnings surprises has a big impact on the markets, says Jim Cramer.
Investors in biotech stocks appear to be happy with a Trump win and Mizuho's senior biotech analyst says companies in the sector could continue to climb in 2017.
Doug Kass shares his thoughts on contrariness and his takeaways and observations on the market.
In highlights from this week's trading diary and posts, Kass tells us about how to say no to closed-end muni bond funds and why Cara Therapeutics is on a run.
With the election resolved, biotech could be ripe for consolidation.
Close out and roll recommendations on trades expiring Friday.
I would look for GILD to try to stabilize in the $70-$80 area before a more durable uptrend.
For as much as we love and respect you, Gilead, the current situation is unacceptable. The once great and mighty biotech Gilead cannot trade at a 6x forward earnings multiple!
Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of James R.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced top-line results from two Phase 3 clinical trials (SIMPLIFY 1 and 2) evaluating momelotinib, an investigational inhibitor of Janus kinase (JAK) compared to ruxolitinib or...
Two pharmaceutical companies, Gilead Sciences and Merck, offer some of the best yields in their sector.
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that John F.
Gilead Sciences (Nasdaq:GILD) today announced detailed results from an open-label Phase 2 trial evaluating the investigational apoptosis signal-regulating kinase 1 (ASK1) inhibitor selonsertib (formerly GS-4997) alone or in...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), has adopted a positive opinion on the...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.
Stocks close at session highs on Wednesday as the idea of a Trump presidency settles in. Financial and health care sectors lead the market.
Stocks post solid gains Wednesday after plunging overnight following Donald Trump's surprising victory in the U.S. presidential race.
Stocks turn positive Wednesday as investors gauge a Donald Trump presidency on markets. Drug, biotech and financial stocks jump.